Opciones terapéuticas para los pacientes con hepatitis C crónica y fracaso terapéutico previo
Neil D. Shah, Michael W. Fried – 10 November 2016
Percutaneous creation of biliary‐enteric neoanastomosis for anastomotic biliary occlusion following living donor liver transplantation
Colin J. McCarthy, Ashraf Thabet, Kei Yamada, Peter R. Mueller, Parsia A. Vagefi – 10 November 2016
The increasing burden of NAFLD fibrosis in the general population: Time to bridge the gap between hepatologists and primary care
Marloes van Asten, Pauline Verhaegh, Ger Koek, Jef Verbeek – 10 November 2016
High prevalence of nonalcoholic fatty liver disease in the middle east: Lifestyle and dietary habits
Ahad Eshraghian – 10 November 2016
Revisión de los tratamientos farmacológicos actuales y futuros de la esteatohepatitis no alcohólica
Ahmed Akhter, Abhishek Pulla, Adnan Said – 10 November 2016
Acute hepatitis E virus infection in patients with acute liver failure in China: Not quite an uncommon cause
Lin Wang, Jiabao Geng – 10 November 2016
Reply
James Hamilton, Svetlana Lutsenko – 10 November 2016
El hígado en la enfermedad sistémica: sepsis y enfermedad crítica
William Bernal – 10 November 2016
From NAFLD to HCC: Is IL‐17 the crucial link?
Maximilian Hatting, Frank Tacke – 7 November 2016
Deregulated neddylation in liver fibrosis
Imanol Zubiete‐Franco, Pablo Fernández‐Tussy, Lucía Barbier‐Torres, Jorge Simon, David Fernández‐Ramos, Fernando Lopitz‐Otsoa, Virginia Gutiérrez‐de Juan, Sergio López de Davalillo, Antonio Martín Duce, Paula Iruzubieta, Daniel Taibo, Javier Crespo, Juan Caballeria, Erica Villa, Igor Aurrekoetxea, Patricia Aspichueta, Marta Varela‐Rey, Shelly C Lu, José M. Mato, Naiara Beraza, Teresa C. Delgado, María L Martínez‐Chantar – 7 November 2016 – Hepatic fibrosis is a global health problem currently without effective therapeutic approaches.